Signals, Powered By EquityPandit
Torrent Pharmaceuticals has launched its biosimilar Adalimumab in India which is used in treating auto immune disorders, under the brand name ‘Adfrar’.
Torrent Pharmaceuticals said in a statement that the company’s product will be available as pre-filled syringe of 40 mg.
The company however did not provide any details regarding the price at which the biosimilar will available.
Torrent Pharmaceuticals said in that Adalimumab is a preferred therapy for the treatment of auto immune disorders and has wide applications for treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, uclerative colitis and plaque psoriasis among others.
It further added that autoimmune disorders are growing ailments and monoclonal antibodies (MAb’s) are becoming mainstay of treatment.
